Roth/MKM Starts Pelthos Therapeutics (PTHS) at Buy

Roth/MKM analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (NYSE: PTHS) with a Buy rating and a price target of $57.00.

The analyst comments: "We initiate coverage of PTHS with a Buy rating and a 12‑month price target of $57, based on a DCF analysis (25% discount rate and 5x multiple of our projected $104M 2033 operating income). We project growing revenue from Zelsuvmi (launched 3Q25) and Xepi (late 2026 launch) in molluscum contagiosum and impetigo, respectively. PTHS has pro forma cash of $28M (3Q25 cash of $14.2M, plus $18M convertible debt raised in 4Q25, minus $4.2M paid upfront for Xepi in 4Q25), which funds operations to cash flow breakeven by YE26, per our projections, and $18M in debt."

For an analyst ratings summary and ratings history on Pelthos Therapeutics click here. For more ratings news on Pelthos Therapeutics click here.

Shares of Pelthos Therapeutics closed at $27.53 yesterday.

You May Also Be Interested In

• Strategy (MSTR) PT Lowered to $186 at Cantor Fitzgerald
• Royal Caribbean Cruises (RCL) PT Raised to $367 at UBS, Estimates Updated
• Corteva Inc. (CTVA) PT Raised to $100 at BMO Capital 'Despite Overreaction'